Tradipitant is a Small Molecule owned by Vanda Pharmaceuticals, and is involved in 16 clinical trials, of which 12 were completed, 3 are ongoing, and 1 is planned.

Tradipitant (VLY-686, LY-686017) is a neurokinin-1 (NK-1) receptor, antagonist. Neurokinin 1 receptor (NK1R) is a mediator of behavioural stress responses, in alcohol dependence and treatment. NK1R deficiency decreases voluntary alcohol consumption and increases sensitivity to the sedative effects of alcohol. In the skin, tissue-resident cells such as keratinocytes, mast cells and cells of the inflammatory infiltrate including lymphocytes and eosinophils interact with neuronal cells. The drug candidate by antagonizing NK-1R reduces over-stimulation of the NK-1R and ameliorates the condition.

The revenue for Tradipitant is expected to reach a total of $328m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tradipitant NPV Report.

Tradipitant was originated by Eli Lilly and Co and is currently owned by Vanda Pharmaceuticals.

Tradipitant Overview

Tradipitant (VLY-686, LY-686017) is under development for the treatment of  gastroparesis, functional dyspepsia and motion sickness. It is administered through oral route as a capsule. The drug candidate is a new chemical entity that targets neurokinin-1 (NK-1) receptor. LY-686017 was also under development for the treatment of anxiety, social phobia, craving during anxiety associated alcohol dependence and treatment-resistant pruritus in atopic dermatitis.

It was under development for the treatment of pneumonia associated with Coronavirus disease 2019 (COVID-19).

Vanda Pharmaceuticals Overview

Vanda Pharmaceuticals (Vanda) a biopharmaceutical company that develops and commercializes novel therapies for the treatment of central nervous system disorders. The company’s products include Hetlioz, a melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a typical antipsychotic for the treatment of schizophrenia in adults. Its major pipeline products include Tradipitant (VLY-686), VTR-297, VQW-765, CFTR and portfolio of cystic fibrosis transmembrane conductance regulator inhibitors and activators. Vanda is headquartered in Washington, Washington DC, the US.

The company reported revenues of (US Dollars) US$268.7 million for the fiscal year ended December 2021 (FY2021), an increase of 8.3% over FY2020. In FY2021, the company’s operating margin was 15.7%, compared to an operating margin of 11% in FY2020. In FY2021, the company recorded a net margin of 12.3%, compared to a net margin of 9.4% in FY2020. The company reported revenues of US$65.3 million for the third quarter ended September 2022, an increase of 1.4% over the previous quarter.

Quick View – Tradipitant

Report Segments
  • Innovator
Drug Name
  • Tradipitant
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Gastrointestinal
  • Infectious Disease
Key Companies
Highest Development Stage
  • Phase III


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.